Shares of blue-chip pharmaceutical company Merck (NYSE:MRK) have been clobbered (in big pharma terms) since reporting earnings on Friday. With the stock down more than 5% since that report, some investors might be looking to take action.
In the video below, health care bureau chief Brenton Flynn offers his opinion of Merck today, and whether investors should take the money and run -- or back up the truck and buy more.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.